Alpha 2.0
Login Register
» Articles » PMID: 24980964

Ceritinib: First Global Approval

Overview
Journal Drugs
Specialty Pharmacology
Date 2014 Jul 2
PMID 24980964
Citations 17
Authors
Sohita Dhillon
Madeleine Clark
Affiliations
Soon will be listed here.
Abstract

Ceritinib is an oral anaplastic lymphoma kinase (ALK) inhibitor developed by Novartis for the treatment of tumours characterised by genetic abnormalities in ALK. ALK is a member of the insulin receptor family of tyrosine kinases that can become oncogenic when fused to other proteins. Ceritinib has been approved in the US under 'Breakthrough Therapy' designation for the second-line treatment of ALK-positive non-small cell lung cancer (NSCLC). Regulatory submissions have also been made in the EU and other countries. Phase III development is ongoing worldwide to evaluate ceritinib both as a first- and second-line therapy for ALK-positive NSCLC. This article summarizes the milestones in the development of ceritinib leading to this first approval for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.

Citing Articles

Oligoethylene Phosphoramidate-Based Kinase Inhibitor Prodrugs - Solubility, Enzyme Inhibition, and Hydrolysis.

Spiewok S, Schaefer M, Lamla M, Jaritz Y, Kuehne A, Kuehne A Chemistry. 2025; 31(12):e202404618.

PMID: 39817527 PMC: 11855230. DOI: 10.1002/chem.202404618.

Nonsmall-cell lung cancer treatment: current status of drug repurposing and nanoparticle-based drug delivery systems.

Inci T, Acar S, Turgut-Balik D Turk J Biol. 2024; 48(2):112-132.

PMID: 39051063 PMC: 11265851. DOI: 10.55730/1300-0152.2687.

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.

Xiang Y, Liu X, Wang Y, Zheng D, Meng Q, Jiang L Front Immunol. 2024; 15:1366260.

PMID: 38655260 PMC: 11035781. DOI: 10.3389/fimmu.2024.1366260.

Reductive coupling of nitro compounds with boronic acid derivatives: an overview.

Behmagham F, Abdullah M, Azimi S, Ubaid M, Ali A, Adhab A RSC Adv. 2023; 13(47):33390-33402.

PMID: 37964904 PMC: 10642445. DOI: 10.1039/d3ra05100e.

Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta-analysis.

Qie W, Zhao Q, Yang L, Zou B, Duan Y, Yao Y Cancer Med. 2023; 12(13):13873-13884.

PMID: 37017467 PMC: 10358266. DOI: 10.1002/cam4.5913.

References
1.
Pillai R, Ramalingam S . The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation. Curr Oncol Rep. 2012; 14(2):105-10. DOI: 10.1007/s11912-012-0213-4. View
2.
Friboulet L, Li N, Katayama R, Lee C, Gainor J, Crystal A . The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014; 4(6):662-673. PMC: 4068971. DOI: 10.1158/2159-8290.CD-13-0846. View
3.
Shaw A, Kim D, Mehra R, Tan D, Felip E, Chow L . Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 370(13):1189-97. PMC: 4079055. DOI: 10.1056/NEJMoa1311107. View
4.
Roskoski Jr R . Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res. 2012; 68(1):68-94. DOI: 10.1016/j.phrs.2012.11.007. View
5.
Shaw A, Solomon B . Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 2011; 17(8):2081-6. DOI: 10.1158/1078-0432.CCR-10-1591. View